Zimmer Biomet Resolves Chinese Plant Warning Letter
Executive Summary
The warning letter referred to CAPA and quality assurance issues at a surgical instruments manufacturing plant in China.
You may also be interested in...
Zimmer Biomet: Large Joint Leader
Just over a month after saying it was going public again, Biomet Inc. is now to be acquired by number-three orthopedic player Zimmer Holdings Inc. for $13.35 billion in a combination of cash and stock. The purchase looks set to catapult Zimmer to the number-two position in the orthopedics market.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.